At the ESMO 2025 Congress, PRIME-ROSE partners highlighted the significance of European collaboration in advancing PCM.
PRIME-ROSE is present at ESMO 2025! Activities include talks, poster presentations and a networking gathering.
FOCU.SE is a new Swedish study where genetic analysis of tumours is used to match cancer patients with targeted drugs.
PRIME-ROSE present at two major oncology events this autumn: ESMO MAP in Paris and ESMO 2025 in Berlin
PRIME-ROSE has established a dedicated data-sharing team that have regular, monthly meetings.
PRIME-ROSE is unlocking the power of connectivity through advancing data sharing.
Missed any updates or just exploring? Take a look through our archive!
New publication by Kjetil Taskén and Piers Mahon published in Nature Reviews Drug Discovery.
PRIME-ROSE was active during the ESMO conference in Barcelona in September 2024.
PRIME-ROSE is present at EMSO 2024! Activities include talks, posters presentations and a networking gathering.
PRIME-ROSE and PCM4EU gathered in Porto, hosted by consotium member IPOPorto.
Community experts gathered in Oslo for the first Community Advisory Board of the DRUP-Like Clinical Trial Community.
Combining expertise across boarders to implement equitable and sustainable precision cancer medicine published Dec 2023
October 20-24
Madrid 20-24 October
Kick-off in Oslo 19-20 September
The official kick-off event for PRIME-ROSE will take place on September 19-20 in Oslo, Norway.
The PRIME-ROSE-project was approved by the European Commission on April 23 2023.
